Loading…
← CockpitCompetitor Analysis › INNV InnovAge Holding Corp.Open in the cockpit ↗

InnovAge Holding Corp.INNVCompetitor analysis, valuation and peers

United States · USD·Information Technology›Packaged Software

Runs PACE centers giving frail seniors all-inclusive medical, social and transportation care so they can stay home.

Momentum neutral 53
Mkt cap
$1.22B
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$4.79M
20-day average traded
Fwd P/E
19.7×
forward earnings
ROIC−WACC
+18.8 pp
WACC 6.5%
Hurdle
-16 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · USD$8.91
1D-5.4%
1W-6.2%
1M-2.6%
3M-16.9%
6M+18.6%
YTD+71.7%
1Y+79.3%
ATR %5.1%
Beta0.78
52w lowhigh29.5% off high

What InnovAge does

Runs PACE centers giving frail seniors all-inclusive medical, social and transportation care so they can stay home.

Receives a fixed monthly payment per enrolled senior from Medicare and the state Medicaid programme, and must cover all that person's care out of it, so profit depends on keeping medical costs below the payment. Growth depends on enrolling more members and on regulators approving expansions; it listed in 2021.

Products and services

  • PACE day-center care
  • Primary/specialty clinical care
  • Transportation & social services

Customers

  • Medicare/Medicaid dual-eligible seniors

Where it sits in the supply chain

  • Senior care services
  • PACE (Program of All-Inclusive Care for…
  • Managed care + clinic operations

What could go right

  • Aging population/dual-eligible growth
  • New state/market expansion

What could go wrong

  • Regulatory/compliance scrutiny (past CMS issues)
  • Capitated cost overruns

Moat: narrow (regulatory licence, installed base). PACE is a capped, state-licensed model; incumbents hold scarce enrollment slots and centers.

Headquarters: Denver, Colorado, US · Employees: 2,500

Named competitors

  • ChenMed private or unlisted
  • CenterWell (Humana) HUM
  • WelbeHealth private or unlisted
  • Trinity Health PACE private or unlisted

InnovAge at a glance

Size InnovAge (INNV) is a United States Information Technology company (Packaged Software) with a market value of $1.22B, the 2109th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.91 on 18 Nov 2026.

Performance Over six months the shares gained 18.6%, against -20.1% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 15.1% over the last twelve months (peer median +8.1%); the operating margin is 7.7% (peer median 4.1%).

Valuation It trades at 19.7× forward earnings against a peer median of 23.2× (6th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.8 points above its cost of capital (6.5% WACC).

Short interest Short interest is 0.7% of the free float (30 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026INNV 121Peer median 79
Six months, rebased to 100: InnovAge against the median of its 20 peers (local-currency closes).

InnovAge financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$1.02B$990M$854M$764M$688M
Revenue growth—+16%+12%+11%—
Gross profit$218M$207M$134M$113M$85.9M
EBITDA$99.9M$87.4M$26.6M$1.73M-$18.5M
Net income$9.00M-$2.54M-$30.3M-$21.3M-$40.7M
Free cash flow$76.3M$50.4M$26.6M-$44.8M-$3.12M
Capital expenditure$13.2M$14.3M$6.26M$7.91M$23.4M
Total debt$83.9M$87.0M$101M$113M$109M

Quarterly statements and history in the cockpit →

InnovAge competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%-10%0%CYIENT300624600198MTG-A300768300634OPRACHG4478PD3006823003786882276682CRSR600446301382000676ZENSARTECHINNV6-month return →1-month return →
Up and to the right = strong over both horizons. InnovAge is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×50×100×150×CYIENTMTG-A300768300634OPRA4478PD3003786682CRSR600446ZENSARTECHINNVRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InnovAge is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%100%CYIENTMTG-A300768300634CHG44783006822672CRSR000676INNVGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InnovAge is the large dot.

InnovAge competitors and peer comparison

Head to head with its named competitors (INNV vs HUM)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
InnovAge INNV$1.22B+19%+15%8%19.7×-6.5%
Humana HUM$46.3B+27%+22%2%22.1×5.5%

How InnovAge compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InnovAge against its 20 peers (data as of 18 Nov 2026)
MeasureINNVPeer medianRank in peer set
1-month return-2.6%-10.2%4th highest of 21
6-month return+18.6%-20.1%6th highest of 20
Distance from 52-week high-29.5%-46.0%6th highest of 21
Revenue growth (TTM)+15.1%+8.1%8th highest of 21
Operating margin7.7%4.1%8th highest of 21
Forward P/E19.7×23.2×6th cheapest of 14
Growth the price implies (Req g, 7 yrs)-6.5%20.1%2nd least demanding of 14
Growth delivered (Del g)+9.2%+18.2%6th lowest of 14
Hurdle (Req g minus delivered)-15.7 pp+8.1 pp4th least demanding of 14
ROIC minus cost of capital+18.8 pp-6.6 pphighest of 20
EV / EBITDA11.7×12.8×4th cheapest of 9
Net debt / EBITDA-0.8×-0.3×5th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InnovAge INNVUnited States$1.22B+19%+15%8%19.7×-6.5%+9.2%
Cyient CYIENT.NSIndia$1.22B+20%+10%9%19.8×20.1%+12.0%
Wondershare Technology 300624.SZChina$1.21B-34%-8%-12%n/an/an/a
Datang Telecom Technology 600198.SSChina$1.21B-34%-11%-30%n/an/an/a
Modern Times Group MTG MTG-A.STSweden$1.22B+12%+21%11%7.4×-8.1%+23.7%
Hangzhou DPTech Technology 300768.SZChina$1.23B-25%-3%5%38.6×32.3%+6.5%
Richinfo Technology 300634.SZChina$1.19B-24%-11%10%28.7×19.2%+19.9%
Opera Limited Sponsored ADR OPRAUnited States$1.24B-20%+23%16%11.8×3.8%+30.1%
CHAPTERS CHG.DEGermany$1.24B+36%+63%-21%n/a43.8%+178.6%
freee K.K 4478.TJapan$1.19B+50%+26%4%55.3×41.6%+32.8%
PagerDuty PDUnited States$1.24B+121%+2%7%11.2×13.4%+18.2%
Longshine Technology 300682.SZChina$1.24B-45%+7%-9%23.2×46.5%+6.0%
Digiwin 300378.SZChina$1.26B-17%+10%9%26.3×n/an/a
Baige Online Digital Technology 2672.HKHong Kong$1.18Bn/a+34%-3%n/a53.3%+41.4%
Bingo Software 688227.SSChina$1.17B-29%-7%-11%n/an/an/a
Phancy 6682.HKHong Kong$1.26B-45%+42%-5%74.9×n/an/a
Corsair Gaming CRSRUnited States$1.27B+69%+2%3%15.1×22.2%-2.9%
Shenzhen Kingdom Sci-tech 600446.SSChina$1.27B-28%-22%-6%159.9×n/an/a
Fengzhushou 301382.SZChina$1.16B-42%+28%8%n/an/an/a
Genimous Technology 000676.SZChina$1.15B-11%+3%6%n/a11.8%-17.5%
Zensar Technologies ZENSARTECH.NSIndia$1.28B+7%+9%14%15.7×11.7%+8.5%

Questions

Who are InnovAge's main competitors?
Named competitors: ChenMed (private or unlisted), CenterWell (Humana) (HUM), WelbeHealth (private or unlisted), Trinity Health PACE (private or unlisted). The cockpit's measured peer set (industry) also includes Cyient (CYIENT.NS), Wondershare Technology (300624.SZ), Datang Telecom Technology (600198.SS), Modern Times Group MTG (MTG-A.ST), Hangzhou DPTech Technology (300768.SZ), Richinfo Technology (300634.SZ).
Is InnovAge expensive compared with its peers?
On forward p/e it trades at 19.7× against a peer median of 23.2×, 6th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has InnovAge stock performed?
Over six months to 18 Nov 2026 the shares returned +18.6% against -20.1% for the median peer; over one year +79.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.